Individual generic drug information
Extracted information for Mefenamic acid only.
Pain and inflammation in rheumatoid arthritis and osteoarthritis | Postoperative pain | Mild to moderate pain ▶BY MOUTH ▶Adult: 500 mg 3 times a day Acute pain including dysmenorrhoea | Menorrhagia ▶BY MOUTH ▶Child 12–17 years: 500 mg 3 times a day ▶Adult: 500 mg 3 times a day
Source page 1230
Active gastro-intestinal bleeding. active gastro-intestinal ulceration. following coronary artery bypass graft (CABG) surgery. history of gastro- intestinal bleeding related to previous NSAID therapy. history of gastro-intestinal perforation related to previous NSAID therapy. history of recurrent gastro-intestinal haemorrhage (two or more distinct episodes). history of recurrent gastro-intestinal ulceration (two or more distinct episodes). inflammatory bowel disease. severe heart failure
Source pages 1230, 1231
Acute porphyrias p. 1120. allergic disorders. cardiac impairment (NSAIDs may impair renal function). cerebrovascular disease. coagulation defects. connective- tissue disorders. dehydration (risk of renal impairment). elderly (risk of serious side-effects and fatalities). epilepsy . heart failure. history of gastro-intestinal disorders (e.g. ulcerative colitis, Crohn’s disease). ischaemic heart disease. peripheral arterial disease. risk factors for cardiovascular events. uncontrolled hypertension
Source page 1231
Contra-indicated in patients with a history of hypersensitivity to aspirin or any other NSAID—which includes those in whom attacks of asthma, angioedema, urticaria or rhinitis have been precipitated by aspirin or any other NSAID.
Source page 1231
Extracted information for Mefenamic acid only.
→Appendix 1: NSAIDs
Source page 1231
Agranulocytosis. anaemia. angioedema. appetite decreased. asthma. bone marrow disorders. confusion. constipation. Crohn’s disease. depression. diarrhoea (discontinue). disseminated intravascular coagulation. dizziness. drowsiness. dyspnoea. dysuria. ear pain. eosinophilia. eye irritation. fatigue. fertility decreased female. gastrointestinal discomfort. gastrointestinal disorders. glomerulonephritis. glucose tolerance impaired. haemolytic anaemia. haemorrhage. hallucination. headache. heart failure. hepatic disorders. hyperhidrosis. hypersensitivity. hypertension. hyponatraemia. hypotension. insomnia. leucopenia. malaise. meningitis aseptic (patients with connective- tissue disorders such as systemic lupus erythematosus may be especially susceptible). multi organ failure. nausea. nephritis acute interstitial. nephrotic syndrome. nervousness. neutropenia. oedema. optic neuritis. oral ulceration. palpitations. pancreatitis. paraesthesia. photosensitivity reaction. proteinuria. rash (discontinue). renal failure (more common in patients with pre-existing renal impairment). renal failure non-oliguric. renal papillary necrosis. respiratory disorders. seizure. sepsis. severe cutaneous adverse reactions (SCARs). skin reactions. thrombocytopenia. tinnitus. vertigo. vision disorders. vomiting SIDE-EFFECTS, FURTHER INFORMATION For information about cardiovascular and gastrointestinal side-effects, and a possible exacerbation of symptoms in asthma, see Non- steroidal anti-inflammatory drugs. p. 1193 Overdose Mefenamic acid has important consequences in overdosage because it can cause convulsions, which if prolonged or recurrent, require treatment. For details on the management of poisoning, see Emergency treatment of poisoning p. 1430, in particular, Convulsions.
Source page 1231
Caution—long-term use of some NSAIDs is associated with reduced female fertility, which is reversible on stopping treatment.
Source page 1231
Avoid unless the potential benefit outweighs the risk. Avoid during the third trimester (risk of closure of fetal ductus arteriosus in utero and possibly persistent pulmonary hypertension of the newborn); onset of labour may be delayed and duration may be increased.
Source page 1231
Use with caution during breast-feeding. Amount too small to be harmful but manufacturer advises avoid.
Source page 1231
Manufacturer advises caution in mild to moderate impairment; avoid in severe impairment.
Source page 1231
Avoid if possible or use with caution. Avoid in severe impairment. Dose adjustments The lowest effective dose should be used for the shortest possible duration. Monitoring In renal impairment monitor renal function; sodium and water retention may occur and renal function may deteriorate, possibly leading to renal failure.
Source page 1231
Extracted information for Mefenamic acid only.
There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension Oral suspension CAUTIONARY AND ADVISORY LABELS 21 EXCIPIENTS: May contain Ethanol Musculoskeletal system ▶Mefenamic acid (Non-proprietary) Mefenamic acid 10 mg per 1 ml Mefenamic acid 50mg/5ml oral suspension | 125 ml P £179.00 DT = £179.00 Tablet CAUTIONARY AND ADVISORY LABELS 21 ▶Mefenamic acid (Non-proprietary) Mefenamic acid 500 mg Mefenamic acid 500mg tablets | 28 tablet P £60.00 DT = £25.82 | 84 tablet P £77.00–£170.00 ▶Ponstan (Chemidex Pharma Ltd) Mefenamic acid 500 mg Ponstan Forte 500mg tablets | 100 tablet P £15.72 Capsule CAUTIONARY AND ADVISORY LABELS 21 ▶Mefenamic acid (Non-proprietary) Mefenamic acid 250 mg Mefenamic acid 250mg capsules | 100 capsule P £60.10 DT = £22.64 ▶Ponstan (Chemidex Pharma Ltd) Mefenamic acid 250 mg Ponstan 250mg capsules | 100 capsule P £8.17 DT = £22.64
Source page 1231
Filter the extracted dose blocks for this individual drug.
First line only; read the complete Indications and dose section above.
500 mg 3 times a day
This is a first-line fragment. Read the full Indications and Dose section above.
Candidate age grouping · source page 1230
